Xlife Sciences AG (FRA:XLS) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XLS Xlife Sciences AG FRA:XLS
59 GF Score
Price €18.80
GF Value €7.62
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

FRA:XLS
59GF Score
Xlife Sciences AG FRA:XLS
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of €18.80 is trading 146.7% above its estimated GF Value™ of €7.62. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for FRA:XLS:

  • Interest Expense (Positive):
  • GF Value™: €7.62 vs. price of €18.80 (146.7% above fair value)
  • GF Score™: 59/100 with 10 warning signs

No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Switzerland
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
59GF Score

Get the complete analysis for FRA:XLS

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.80
Price
€7.62
GF Value